Alec Stranahan
BofA Securities, Research Division

Thanks, everyone, for joining this session with Perspective Therapeutics. My name is Alec Stranahan. I'm senior biotech analyst at Bank of America covering Perspective. And I'm pleased to be joined today by Joel Sendek, Chief Financial Officer of Perspective. Thanks for being here, Joel.

Joel Sendek
CFO & Principal Financial Officer

Thanks a lot, Alec. We really appreciate being invited to the conference. It's been a great day.

Alec Stranahan
BofA Securities, Research Division

Yes. Great. Great to hear it. So we've got 30 minutes here for our fireside. Maybe we can start just at a high level, Perspective is today one of the only vertically integrated targeted alpha therapy companies. You're developing RLTs for a variety of indications. I guess when you think about the moat that you're building around your technology and your clinical programs, where are the biggest sort of differentiation points, either on the tech side or in terms of your clinical assets, just to set the stage?

Joel Sendek
CFO & Principal Financial Officer

Sure thing. You said we only had 30 minutes. I mean, I think we're going to take 40 minutes on that question alone. No, it's -- at a very high level, I think we're, as you said, one of the only vertically integrated radio pharmaceutical companies our size right now. And I certainly can't take credit for it. I've all been in the company in 9 months but a lot of this is vision that's being -- has been executed over the last couple of years. It's only now coalescing in a way that enables us to really approach the